The therapeutic efficacy of Anastrozole can be decreased when used in combination with Methallenestril. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Quinestrol. The serum concentration of Rilpivirine can be increased when it is combined with Anastrozole. The serum concentration of Bosutinib can be increased when it is combined with Anastrozole. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Secoisolariciresinol. The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Anastrozole. Bevacizumab may increase the cardiotoxic activities of Anastrozole. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Synthetic Conjugated Estrogens, A. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Tibolone. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Diethylstilbestrol. Trastuzumab may increase the cardiotoxic activities of Anastrozole. The serum concentration of Mevastatin can be increased when it is combined with Anastrozole. Acetyldigitoxin may decrease the cardiotoxic activities of Anastrozole. Digitoxin may decrease the cardiotoxic activities of Anastrozole. The risk or severity of adverse effects can be increased when Ergotamine is combined with Anastrozole. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Mestranol. The serum concentration of Ubidecarenone can be increased when it is combined with Anastrozole. Ouabain may decrease the cardiotoxic activities of Anastrozole. Proscillaridin may decrease the cardiotoxic activities of Anastrozole. The risk or severity of adverse effects can be increased when Methysergide is combined with Anastrozole. The risk or severity of adverse effects can be increased when Pergolide is combined with Anastrozole. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Genistein. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estriol. The serum concentration of Anastrozole can be decreased when it is combined with Tamoxifen. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Anastrozole. The risk or severity of adverse effects can be increased when Bromocriptine is combined with Anastrozole. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Hexestrol. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Ethinyl Estradiol. The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Anastrozole. Digoxin may decrease the cardiotoxic activities of Anastrozole. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estrogens, esterified. The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Anastrozole. The risk or severity of adverse effects can be increased when Cabergoline is combined with Anastrozole. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estradiol. The risk or severity of adverse effects can be increased when Anastrozole is combined with Atorvastatin. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Dienestrol. Cyclophosphamide may increase the cardiotoxic activities of Anastrozole. The serum concentration of Simvastatin can be increased when it is combined with Anastrozole. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estrone. The serum concentration of Pitavastatin can be increased when it is combined with Anastrozole. The serum concentration of Methadone can be increased when it is combined with Anastrozole. The risk or severity of adverse effects can be increased when Methylergometrine is combined with Anastrozole. The risk or severity of adverse effects can be increased when Ergonovine is combined with Anastrozole. The serum concentration of Lovastatin can be increased when it is combined with Anastrozole. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Promestriene. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Equol. The serum concentration of Cerivastatin can be increased when it is combined with Anastrozole. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Synthetic Conjugated Estrogens, B. The serum concentration of Pravastatin can be increased when it is combined with Anastrozole. The serum concentration of Ibrutinib can be increased when it is combined with Anastrozole. The risk or severity of adverse effects can be increased when Docetaxel is combined with Anastrozole. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Conjugated estrogens. The serum concentration of Rosuvastatin can be increased when it is combined with Anastrozole. Oleandrin may decrease the cardiotoxic activities of Anastrozole. The therapeutic efficacy of Anastrozole can be decreased when used in combination with Chlorotrianisene. Deslanoside may decrease the cardiotoxic activities of Anastrozole. The risk or severity of adverse effects can be increased when Nicergoline is combined with Anastrozole. Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Anastrozole. The serum concentration of Tizanidine can be increased when it is combined with Anastrozole. The serum concentration of Tolvaptan can be increased when it is combined with Anastrozole. The risk or severity of adverse effects can be increased when Metergoline is combined with Anastrozole. The serum concentration of Fluvastatin can be increased when it is combined with Anastrozole. The risk or severity of adverse effects can be increased when Lisuride is combined with Anastrozole.